Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Slides:

Advertisements

Similar presentations

Use of the insulin pump in treat cystic fibrosis related diabetes Dana S. Hardin, Julie Rice, Mark Rice, Randall Rosenblatt Journal of Cystic Fibrosis.

Advertisements

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Cheryl Cameron, Mark W. Lodes, William M. Gershan

The prevalence of “risky behaviour” in adults with cystic fibrosis

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Christopher C. Miller, Christopher A

Cystic Fibrosis Foundation and European Cystic Fibrosis Society Survey of cystic fibrosis mental health care delivery J. Abbott, J.S. Elborn, A.M. Georgiopoulos,

Infections in Patients with Cystic Fibrosis

Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients Helle Krogh Johansen, Samuel.

Is infection with hypermutable Pseudomonas aeruginosa clinically significant? Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir

Cystic fibrosis research in allied health and nursing professions

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

A. Mirakhur, M.J. Gallagher, M.J. Ledson, C.A. Hart, M.J. Walshaw

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

The Journal of Cystic Fibrosis: Sunny perspectives

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Valerie Waters, Eshetu G

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI®

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions Gerard McCaughey,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment Matthias Kappler,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

G.C. Schito Clinical Microbiology and Infection

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Treatment intensity and characteristics of MRSA infection in CF

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Segregation—the perspectives of young patients and their parents

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of Cystic Fibrosis Volume 8, Issue 3, Pages 211-217 (May 2009) DOI: 10.1016/j.jcf.2009.03.001 Copyright © 2009 Terms and Conditions

Fig. 1 Point of intervention with nebulized antibiotics following infection with Pseudomonas aeruginosa (multiple responses possible per respondent). Journal of Cystic Fibrosis 2009 8, 211-217DOI: (10.1016/j.jcf.2009.03.001) Copyright © 2009 Terms and Conditions

Fig. 2 Antibiotic treatment regimens employed by respondents in order to treat or eradicate Pseudomonas aeruginosa. Journal of Cystic Fibrosis 2009 8, 211-217DOI: (10.1016/j.jcf.2009.03.001) Copyright © 2009 Terms and Conditions

Fig. 3 Treatment strategies for a) intermittent Pseudomonas aeruginosa infection, and b) chronic P. aeruginosa infection. Journal of Cystic Fibrosis 2009 8, 211-217DOI: (10.1016/j.jcf.2009.03.001) Copyright © 2009 Terms and Conditions

Fig. 4 Indication for initiating treatment for Staphylococcus aureus, as highlighted by survey respondents. Journal of Cystic Fibrosis 2009 8, 211-217DOI: (10.1016/j.jcf.2009.03.001) Copyright © 2009 Terms and Conditions